LENALIDOMIDE
lenalidomide 20 mg capsule, 21
LENALIDOMIDE (14633E)
14633E
Manner of administration:Oral
Restriction
Indication: Multiple myeloma
Treatment phase: Continuing treatment of triple therapy (this drug, bortezomib and dexamethasone) for
treatment cycles 5 and 6 (administered using 28-day treatment cycles)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 21 | # of repeats: 1 | DPMQ: $757.74 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||